Jim Simons
MREO

Jim Simons’s Mereo BioPharma MREO Stock Holding History

Jim Simons’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16K Sell
48,400
-145,971
-75% -$62.6K ﹤0.01% 3182
2025
Q4 		$81K Sell
194,371
-396,500
-67% -$755K ﹤0.01% 3034
2025
Q3 		$1.22M Sell
590,871
-889,600
-60% -$1.64M ﹤0.01% 2384
2025
Q2 		$4.01M Buy
1,480,471
+130,000
+10% +$314K 0.01% 1659
2025
Q1 		$3.04M Buy
1,350,471
+161,000
+14% +$455K ﹤0.01% 1732
2024
Q4 		$4.16M Sell
1,189,471
-115,900
-9% -$455K 0.01% 1565
2024
Q3 		$5.37M Sell
1,305,371
-456,632
-26% -$1.89M 0.01% 1404
2024
Q2 		$6.34M Buy
1,762,003
+89,694
+5% +$291K 0.01% 1165
2024
Q1 		$5.52M Sell
1,672,309
-125,700
-7% -$426K 0.01% 1355
2023
Q4 		$4.15M Buy
1,798,009
+70,439
+4% +$135K 0.01% 1468
2023
Q3 		$2.23M Sell
1,727,570
-51,202
-3% -$67.9K ﹤0.01% 1795
2023
Q2 		$2.35M Buy
1,778,772
+862,863
+94% +$1M ﹤0.01% 1891
2023
Q1 		$647K Sell
915,909
-341,460
-27% -$307K ﹤0.01% 2734
2022
Q4 		$943K Buy
1,257,369
+23,755
+2% +$19.5K ﹤0.01% 2570
2022
Q3 		$1.06M Buy
1,233,614
+624,705
+103% +$764K ﹤0.01% 2460
2022
Q2 		$682K Buy
608,909
+325,109
+115% +$252K ﹤0.01% 2963
2022
Q1 		$318K Buy
283,800
+63,200
+29% +$81.7K ﹤0.01% 3446
2021
Q4 		$353K Sell
220,600
-178,300
-45% -$357K ﹤0.01% 3267
2021
Q3 		$965K Buy
398,900
+113,800
+40% +$301K ﹤0.01% 2573
2021
Q2 		$904K Buy
285,100
+17,900
+7% +$60.1K ﹤0.01% 2717
2021
Q1 		$900K Sell
267,200
-92,000
-26% -$325K ﹤0.01% 2656
2020
Q4 		$1.29M Buy
359,200
+338,000
+1,594% +$847K ﹤0.01% 2374
2020
Q3 		$56K Sell
21,200
-29,200
-58% -$85.3K ﹤0.01% 3265
2020
Q2 		$154K Buy
+50,400
New +$88.9K ﹤0.01% 3207
2020
Q1 		– Sell
-126,323
Closed -$414K – 3664
2019
Q4 		$414K Sell
126,323
-39,800
-24% -$102K ﹤0.01% 2964
2019
Q3 		$495K Sell
166,123
-29,800
-15% -$90.1K ﹤0.01% 2872
2019
Q2 		$494K Buy
+195,923
New +$857K ﹤0.01% 3005

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Jim Simons's MREO Position: Q1 2026 in Review

Jim Simons reduced its Mereo BioPharma (MREO) stake by 75% in Q1 2026, selling an estimated $62.6K and leaving 48,400 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #3182.

Jim Simons first reported a position in MREO in Q2 2019 and has held it in 27 quarters since. The position peaked at $6.34M in Q2 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Jim Simons held 48,400 shares of Mereo BioPharma worth $16K as of Q1 2026.
  • Jim Simons sold 145,971 Mereo BioPharma shares in Q1 2026, an estimated $62.6K.
  • Mereo BioPharma made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #3182 holding.
  • Jim Simons first reported a position in Mereo BioPharma in Q2 2019 and has held it in 27 quarters since.
  • Jim Simons's Mereo BioPharma position peaked at $6.34M in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.